Purified liver extracts have been used for a number of years in the treatment of both acute and chronic liver disease. Ripason, a protein-free liver extract, was introduced in 1953 and has been shown to have beneficial effects in both experimental and clinical studies. Burri (1953) and Hartmann (1953) showed it to have a lipotropic effect in the carbon tetrachloride damaged rat liver and Roulet (1958) , also using rats, demonstrated a protective effect of this extract in the induction of cirrhosis by choline deficiency. In rabbits it may stimulate regeneration of liver parenchyma after partial hepatectomy (Grifoni and Rucci, 1962) .
A large number of clinical reports on the use of oral and parenteral preparations of Ripason have indicated its value in various types of acute and chronic hepatic disease (Paraf, 1954; Stiefel and Jasinski, 1963; Gutewa, 1962; Dioguardi, 1956) . However, all these trials have been uncontrolled and often involved only subjective assessment of the patients' improvement. In this paper we present the results of a double-blind controlled trial of Ripason therapy in chronic liver disease.
DESIGN OF TRIAL
Twenty-four adult patients with histologically proven cirrhosis were admitted to the trial, and were randomly allocated into two groups. At the onset of the trial their liver disease was well compensated and clinically stable. Two died during the early part of the trial, both from hepatomas, one reverted to taking large quantities of alcohol and one was withdrawn because of a sensitivity reaction after the second injection of Ripason.
Twenty patients completed the trial and consisted of two groups receiving either Ripason or placebo on a double-blind basis. Six patients out of the 10 in the Ripason group and seven of the placebo group were males. The two groups contained similar numbers of patients with different varieties of cirrhosis (Table I) and similar numbers of patients with abnormal tests at the onset of the trial (Fig. 1 ). The differences in the means of each measurement between the groups at the beginning of the trial were also not significant. However, the patients in the placebo group were on average 13-2 years older than the patients receiving Ripason (Table 11) , this difference being significant (p < 0-01). We concluded that since the two groups were otherwise well matched the different age distributions represented a chance occurrence due to small numbers and that this would not affect the results of the trial. Similar discrepancies have occurred in trials concerning larger numbers of Each patient was observed on monthly occasions for seven months, twice before treatment was started, three times during treatment, and twice after treatment. At every attendance each patient was asked a series of standard questions regarding general well-being and appetite and was also examined for liver and spleen size, the presence of ascites or ankle oedema, and for signs of porto-systemic encephalopathy. The following measurements were made: weight; haemoglobin; total white cell count; erythrocyte sedimentation rate; total serum bilirubin with conjugated and unconjugated fractions, total plasma proteins with albumin, oil globulin, a2 globulin, P globulin, and y globulin fractions; serum aspartate aminotransferase; alkaline phosphatase; blood urea; serum electrolytes. Bromsulphalein excretion was measured using the method of Seligson, Marino, and Dodson (1957) with samples taken at 5, 10, 20, and 30 minutes, the results being expressed as the halfclearance time in minutes.
Ripason and placebo were administered both parenterally and orally. Each patient received 2 ml of solution by intramuscular injections three times a week for three months and also received two tablets three times a day, three times a week for three months, the tablets being taken on days when the injections were not administered. The placebo injections and tablets contained a 1 in 10,000 solution of Ripason.
At the end of the trial but before the code was broken the patients and the physicians gave a numerical assessment of their overall progress as follows: much better + 2; better + 1; the same 0; worse -1; much worse -2.
RESULTS
In the overall assessment of progress of the Ripason group during the trial the patients' assessment scores gave a total of +9 whereas the physician's assessment (of the corresponding group) was +4. For the placebo group the values were +4 and +2 respectively. Changes in well being and appetite are shown in Table III separately.
The haemoglobin concentration and some of the more important liver function tests were analysed. Those taken were: albumin; serum globulin; serum aspartate aminotransferase (SGOT); alkaline phos- Table IV that there has been no significant change in any of the specific measurements.
The bromsulphalein excretion results have been recorded graphically (Fig. 2) . In one patient in the group on Ripason (indicated by the heavy line) there was a significant improvement over the period of observation and in this case the rather wide variation of the two basal recordings makes the later observations difficult to interpret.
DISCUSSION
In animal experiments this protein-free liver extract Body weight (kg) Haemoglobin (g/ 100 ml) Albumin (g/100 ml) y Globulin (g/100 ml) SGOT (IU/100 ml) Alkaline phosphatase (K-A U/t00 ml) Bilirubin (mg/100 ml) 1 + standard error. Burri (1953) , Harti and Tanyol and Friedman (1961) showii in the degree of fatty infiltration produo tetrachloride poisoning. In man the ben of Ripason has been reported in rr disorders, such as prolonged infecti' compensated cirrhosis, and fatty degene liver (Kallai and Cerlek, 1955 The good symptomatic effect of Ripason has been stressed in earlier publications (Falkner, Hammer-RIPASON schmidt, and Neumayr, 1954) . In our patients an increased sense of well being and an improved appetite were noted in both groups, with a slightly better result in the placebo group. Fewer patients were 'worse' on Ripason than on placebo (Table III) .
Using an arbitrary scoring system for assessment, patients reported greater subjective benefit from Ripason than from placebo treatment. Only one possible reaction was encountered in ye hepatitis, more than 500 injections of full strength and diluted ration of the Ripason. This man developed rigors two to three )st of these hours after his second injection and had to be mprovement withdrawn from the trial. Two other patients n based on complained of skin itching but this was never severe. ntan, 1956 ). This preparation therefore appears to be relatively idy recorded free from side effects whether given intramuscularly al tests and or orally. Finally, although this was a double-blind y improved trial the 'placebo' did contain a very small dose i excretion. of Ripason (1 in 10,000). The possibility that the patients with symptomatic improvement noted in both the ce the course groups was due to trace compounds contained in ;ith cirrhosis the preparation cannot be excluded.
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